The immunohistochemical analysis of xenograft sections obtained eight weeks after implantation showed that the number of Ki-67-positive cells decreased in the residual cancer cells of xenografts treated with everolimus; however, in contrast to rapamycin, the addition of everolimus to GP decreased the number of Ki-67-positive cells in the remaining cancer cells (Fig. 7C). This evidence concerns the gene MKI67 and cancer.